

Severe fluoropyrimidine toxicity due to novel and rare *DPYD* missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing

André B.P. van Kuilenburg, Judith Meijer, Dirk Mauer, Doreen Dobritzsch, Rutger Meinsma, Maartje Los, Lia C. Knegt, Lida Zoetekouw, Rob L.H. Jansen, Vincent Dezentjé, Lieke H. van Huis-Tanja, Roel J.W. van Kampen, Jens Michael Hertz, Raoul C.M. Hennekam

PII: S0925-4439(16)30346-5
DOI: doi:10.1016/j.bbadis.2016.12.010
Reference: BBADIS 64639

To appear in: *BBA - Molecular Basis of Disease*

Received date: 2 November 2016
Accepted date: 20 December 2016

Please cite this article as: André B.P. van Kuilenburg, Judith Meijer, Dirk Mauer, Doreen Dobritzsch, Rutger Meinsma, Maartje Los, Lia C. Knegt, Lida Zoetekouw, Rob L.H. Jansen, Vincent Dezentjé, Lieke H. van Huis-Tanja, Roel J.W. van Kampen, Jens Michael Hertz, Raoul C.M. Hennekam, Severe fluoropyrimidine toxicity due to novel and rare *DPYD* missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing, *BBA - Molecular Basis of Disease* (2016), doi:10.1016/j.bbadis.2016.12.010

Severe fluoropyrimidine toxicity due to novel and rare *DPYD* missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing.

André B.P. van Kuilenburg[1], Judith Meijer[1], Dirk Mauer[2], Doreen Dobritzsch[2], Rutger Meinsma[1], Maartje Los[3], Lia C. Knegt[1], Lida Zoetekouw[1], Rob L.H. Jansen[4], Vincent Dezentjé[5], Lieke H. van Huis-Tanja[6], Roel J.W. van Kampen[7], Jens Michael Hertz[8] and Raoul C.M. Hennekam[1]

[1]Academic Medical Center, University of Amsterdam, Emma Children's Hospital, Departments of Clinical Chemistry, Pediatrics and Clinical Genetics, Laboratory Genetic Metabolic Diseases, Amsterdam, The Netherlands

[2]Uppsala University, Department of Chemistry, Biomedical Center, S-751 24 Uppsala, Sweden

[3]St. Antonius Hospital, Department of Oncology, Nieuwegein, The Netherlands

[4]Maastricht University Medical Center, Department of Oncology, Maastricht, The Netherlands

[5]Reinier de Graaf Gasthuis, Department of Clinical Oncology, Delft, The Netherlands

[6]Diakonessenhuis Utrecht, Department of Oncology, Utrecht, The Netherlands

[7]Zuyderland Medical Center, Department of Oncology, Sittard-Geleen, The Netherlands

[8]Odense University Hospital, Department of Clinical Genetics, Odense C, Denmark

Corresponding author: Dr. A.B.P. van Kuilenburg, Academic Medical Center, Laboratory Genetic Metabolic Diseases, F0-220, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. Tel: +31 205665958, Fax: +31 206962596. E-mail: a.b.vankuilenburg@amc.uva.nl